[Surgical Treatment of Peritoneal Metastases from Gynecological Primary Tumors]

Overview

Journal Chirurg

Specialty General Surgery

Date 2018 Jul 6

PMID 29974140

Authors

P Horvath

A Konigsrainer

Affiliations

Soon will be listed here.

Abstract

Background: The principle of surgical treatment of peritoneal metastases of ovarian cancer in the primary as well as in the recurrent disease setting includes macroscopic complete cytoreductive surgery. The addition of intraperitoneal chemotherapy after cytoreduction is currently not part of the standard treatment.

Objective: Data on intraperitoneal chemotherapy for treatment of peritoneal metastases of ovarian cancer are presented focusing on overall and progression-free survival and on morbidity and mortality rates.

Method: PubMed search including the following terms: ovarian cancer, peritoneal metastases, cytoreduction and HIPEC.

Results: Randomized-controlled and non-randomized controlled trials showed that intraperitoneal chemotherapy after maximum cytoreductive surgery results in a survival benefit regarding overall and progression-free survival for primary as well as recurrent disease. Addition of HIPEC does not impact on the initiation of postoperative systemic chemotherapy.

Conclusion: Macroscopic complete cytoreduction is the most important prognostic factor. The addition of intraperitoneal chemotherapy for the treatment of peritoneal metastases of ovarian cancer showed promising results but so far it is not accepted as a part of a multimodal treatment concept.

References

Gordon A, Fleagle J, GUTHRIE D, Parkin D, Gore M, Lacave A . Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19(14):3312-22. DOI: 10.1200/JCO.2001.19.14.3312. View

Sun J, Ji Z, Yu Y, Wu H, Huang C, Zhang Q . Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established Database. Transl Oncol. 2016; 9(2):130-138. PMC: 4833965. DOI: 10.1016/j.tranon.2016.02.002. View

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E . Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2014; 22(5):1570-5. DOI: 10.1245/s10434-014-4157-9. View

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M . Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012; 107(4):588-91. PMC: 3419956. DOI: 10.1038/bjc.2012.307. View

Deraco M, Virzi S, Iusco D, Puccio F, Macri A, Famulari C . Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012; 119(7):800-9. DOI: 10.1111/j.1471-0528.2011.03207.x. View

Bakrin N, Cotte E, Golfier F, Gilly F, Freyer G, Helm W . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012; 19(13):4052-8. DOI: 10.1245/s10434-012-2510-4. View

Burges A, Schmalfeldt B . Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int. 2011; 108(38):635-41. PMC: 3198226. DOI: 10.3238/arztebl.2011.0635. View

Alberts D, Liu P, Hannigan E, OToole R, Williams S, Young J . Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335(26):1950-5. DOI: 10.1056/NEJM199612263352603. View

Raspagliesi F, Kusamura S, Campos Torres J, de Souza G, Ditto A, Zanaboni F . Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006; 32(6):671-5. DOI: 10.1016/j.ejso.2006.03.011. View

10.

Yang L, Zhang B, Xing G, Du J, Yang B, Yuan Q . Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome. PLoS One. 2017; 12(10):e0186725. PMC: 5653345. DOI: 10.1371/journal.pone.0186725. View

11.

Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen J . A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol. 1993; 49(1):30-6. DOI: 10.1006/gyno.1993.1081. View

12.

Ataseven B, Grimm C, Harter P, Heitz F, Traut A, Prader S . Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol. 2015; 140(2):215-20. DOI: 10.1016/j.ygyno.2015.12.007. View

13.

Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M . Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008; 113(2):315-25. DOI: 10.1002/cncr.23553. View

14.

Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, du Bois A . Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.... Gynecol Oncol. 2007; 106(1):69-74. DOI: 10.1016/j.ygyno.2007.02.026. View

15.

Zang R, Zhang Z, Li Z, Chen J, Tang M, Liu Q . Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000; 75(1):24-30. DOI: 10.1002/1096-9098(200009)75:1<24::aid-jso5>3.0.co;2-l. View

16.

Pfisterer J, Hilpert F, Bois A, Meier W, Wagner U . State-of-the-art first-line treatment of ovarian cancer. Onkologie. 2003; 26(5):446-50. DOI: 10.1159/000072977. View

17.

Harter P, Hahmann M, Lueck H, Poelcher M, Wimberger P, Ortmann O . Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009; 16(5):1324-30. DOI: 10.1245/s10434-009-0357-0. View

18.

Mueller J, Kelly A, Zhou Q, Iasonos A, Long Roche K, Sonoda Y . Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecol Oncol. 2016; 143(3):496-503. PMC: 5624326. DOI: 10.1016/j.ygyno.2016.09.014. View

19.

Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave A . Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24(29):4699-707. DOI: 10.1200/JCO.2006.06.0913. View

20.

Bae J, Lee J, Ryu K, Lee Y, Park Y, Hur S . Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007; 106(1):193-200. DOI: 10.1016/j.ygyno.2007.03.019. View